RE:Looks like Kedrion chose to pass up the option! One would think that insurance companies would have been prepped about this drug coming down the pipe. I also wonder how soon that they could try using Ryplazim on Acute Respiratory Distress Syndrome or Severe Burns offlabel. What are the rules around that usage? I think the expense was carrying those plasma collection facilities but I imagine that they have costs at the Laval plant. it would be informative to have Liminal shed some light around the business model but they just keep investors in the dark which generally leads to a negative interpretation.
stockman6767 wrote: Looks like Kedrion chose to pass up the option!
I imagine, Given that it is now June 16, and the new job postings published by LMLNL means that Kedrion (who knows this market very well) has decided that the negatives of carrying the costs of taking up the option and the costs of carrying PBI and PBT would not be covered by the small revenue stream from the Ryplazim approval, which after all is only a small indication with a small revenue stream, even with the $30 M kicker from the potential sale of the PRV voucher. Remains to be seen what actuallt happens here and whether either LMNL or Kedrion will issue a PR to clarify the situation.